Anticancer drugs continue to cause significant reductions in left ventricular ejection fraction
resulting in congestive heart failure. The best-known cardiotoxic agents are anthracyclines …

Doxorubicin is known to cause cardiomyopathy and congestive heart failure (CHF) upon
chronic administration. A major obstacle to doxorubicin-containing multiagent therapies …

Trastuzumab, a monoclonal antibody that blocks HER-2 receptor, improves the survival of
women with HER-2-positive early and advanced breast cancer when given with …

Many antitumor drugs cause “on treatment” cardiotoxicity or introduce a measurable risk of
delayed cardiovascular events. Doxorubicin and other anthracyclines cause congestive …

Importance of the field: Trastuzumab has become a mainstay in the treatment of women with
human epidermal growth factor receptor-2 (HER2)-overexpressing breast cancer in the …

Purpose Despite great success as a targeted breast cancer therapy, trastuzumab use may
be complicated by heart failure and loss of left ventricular contractile function. This review …

Over the past 20 years, the prognosis of HER2-positive breast cancer has been transformed
by the development of anti-HER2 targeted therapies. In early clinical trials of trastuzumab …

AIM: Trastuzumab can induce cardiotoxicity, particularly when combined with
anthracyclines. Myocardial human epidermal growth factor receptor 2 (HER2) expression …

Human epidermal growth factor receptor-2 (HER2) is a member of the epidermal growth
factor receptor family, which produces factors that are considered to be important mediators …

Trastuzumab is a monoclonal antibody used for the treatment of metastatic breast carcinoma
in women whose tumors overexpress the HER2 protein. Cardiotoxicity has been reported to …